Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma.

Edgar G Kozlova Hsin-Hui Huang Opeyemi A JagedeKevin TuballesDiane M Del Valle Geoffrey Kelly Manishkumar Patel Hui XieJocelyn HarrisKimberly Argueta Kai NieVanessa BarcessatRadim Moravec Jennifer Altreuter Dzifa Yawa Duose Brad S Kahl Stephen M Ansell Joyce Yu Ethan Cerami James R Lindsay Ignacio I Wistuba Seunghee Kim-Schulze Catherine S Diefenbach Sacha Gnjatic

Published in: Cancer research communications (2024)

Identification of multi-omic immune markers from peripheral blood may help elucidate resistance mechanisms to checkpoint inhibitor and antibody-drug conjugate combinations with potential implications for treatment decisions in relapsed HL.

Keyphrases

hodgkin lymphoma
peripheral blood
acute myeloid leukemia
acute lymphoblastic leukemia
dna damage
combination therapy
dna methylation
drug delivery
cell cycle
diffuse large b cell lymphoma
multiple myeloma
smoking cessation